Scioderm Appoints Orphan Product Executives to Board of Directors
DURHAM, N.C., Dec. 2, 2013 /PRNewswire/ -- Scioderm, Inc. announced the appointment of John Crowley and William Aliski to the company's Board of Directors.
As Chairman & CEO of NASDAQ listed Amicus Therapeutics, John brings a significant rare and orphan disease experience to Scioderm, in addition to his in depth transactional and public sector market experience. His personal drive, commitment and overall determination to find cures for rare diseases such as Pompe and Fabry Disease will substantially contribute to the overall success of Scioderm.
William (Bill) Aliski brings over 25 years of senior executive orphan drug commercial management experience most recently with FoldRx Pharmaceuticals, Inc. Prior to that he was General Manager for Biomarin Europe and directed the launch of Naglazyme for MPS VI. He has played a critical leadership role in the launch of other orphan products having spearheaded market access and pricing strategies for companies such as Genzyme and TKT.
"I am most pleased to join the Board of Scioderm and to support the company in its realization of its mission and objectives for its lead orphan pediatric product SD-101 for the treatment of all subtypes of Epidermolysis Bullosa, a rare and debilitating pediatric disease," noted John Crowley. "I hope that my experience and perspectives in the orphan drug space can contribute to ensuring the rapid and successful development of this exciting new compound for people living with EB."
Bill Aliski commented, "I look forwarded to working with the management and Board of Scioderm particularly in supporting the company with the definition and execution of its global commercialization strategy including market access and pricing for its epidermolysis bullosa program, an orphan disease area for which there is currently no treatment and significant unmet need."
"Both John and Bill will be very strong and complementary additions to Scioderm's Board of Directors, based on their extensive experience in the rare disease and orphan drug arena," said Dr. Robert Ryan, Chief Executive Officer of Scioderm. "We look forward to their support and insights towards the realization of the company's planned success. I also wish to thank Christos Richards of Levin & Company, an executive search firm specializing in the life sciences field, for leading the effort in securing the new board members."
Chris Christoffersen, Chairman of the Scioderm Board and General Partner of Morgenthaler Ventures, Scioderm's lead investor commented, "To have two distinguished veterans with extensive experience in orphan diseases join our Board is a wonderful event for Scioderm, and we look forward to working with them to make Scioderm a significant success."
Roger Quy, Board Member and General Partner of Technology Partners commented, "I am delighted that Scioderm has attracted these two outstanding individuals in the field of rare diseases to the Board. It is another indication that the contribution of the Company is becoming more broadly recognized."
About Scioderm and SD-101
Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, including orphan products. The lead product, SD-101,is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. In addition, Scioderm recently received Breakthrough Therapy Designation for SD-101 for treatment of the skin effects in patients with EB, placing the product in a category that may enable expediting of the development program. The company is headquartered in Durham, North Carolina. Additional information about Scioderm can be found at www.sderm.com.
Scioderm Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Scioderm disclaims any intent or obligation to update these forward-looking statements.
Chief Operating Officer